Article
Biochemistry & Molecular Biology
Yingjie Shen, Hyoung Jae Lee, Rui Zhou, Hangun Kim, Gen Chen, Young-Chang Cho, Kwonseop Kim
Summary: Delta-catenin plays a crucial role in prostate cancer by inducing phosphorylation of p21 and stabilizing it in the cytoplasm, thus inhibiting its nuclear accumulation. It also regulates the interaction between AKT and p21, leading to the phosphorylation of p21 at Thr-145 residue, ultimately promoting proliferation and metastasis in prostate cancer through the EGF signaling pathway. These findings provide new insights into potential therapeutics targeting delta-catenin for controlling prostate cancer progression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Cell Biology
Shiqi Wu, Yangyang Yue, Yanan Gu, Qi Wang, Tianjie Liu, Lei Li, Xinyang Wang, Luke S. Chang, Dalin He, Kaijie Wu
Summary: MUC15 acts as a novel tumor suppressor in prostate cancer, inhibiting metastasis by modulating epithelial-mesenchymal transition and cancer stemness.
CELLULAR SIGNALLING
(2021)
Article
Immunology
Qi-Xing Tian, Zhi-Hui Zhang, Qing-Lin Ye, Shen Xu, Qian Hong, Wei-Yang Xing, Lei Chen, De-Xin Yu, De-Xiang Xu, Dong-Dong Xie
Summary: The study reveals that LPS promotes migration and invasion of PCa cells by activating TLR4 downstream pathways, inducing inflammation and EMT. Melatonin inhibits migration and invasion in both LPS-stimulated and -unstimulated PCa cells by blocking EMT-associated pathways mediated by IL-6/STAT3, AKT/GSK-3 beta, and beta-catenin.
JOURNAL OF INFLAMMATION RESEARCH
(2021)
Article
Multidisciplinary Sciences
Ming Yang, Xudong Zhu, Yang Shen, Qi He, Yuan Qin, Yiqun Shao, Lin Yuan, Hesong Ye
Summary: This study successfully established a prognostic model for prostate cancer recurrence-free survival and identified the biomarker GPX2. It revealed that GPX2 regulates the progression of prostate cancer and triggers molecular changes in the Wnt/β-catenin/EMT pathway.
Review
Medicine, Research & Experimental
Jingmei Liu, Wei Yan, Ping Han, Dean Tian
Summary: KIAA1199, also known as CEMIP or HYBID, is an important oncogene associated with tumor progression and metastasis in various malignancies. It plays crucial roles in regulating multiple signaling pathways and could be a potential therapeutic target for cancer therapy.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Oncology
Jun Zhang, Xian Zhang, Shasha Yang, Yanqiu Bao, Dongyuan Xu, Lan Liu
Summary: The study demonstrated that higher FOXH1 expression is associated with poor overall survival in lung cancer patients. Knockdown of FOXH1 inhibited lung cancer cell proliferation, migration, invasion, and cycle, highlighting FOXH1's potential as a therapeutic target in certain types of lung cancer.
CANCER CELL INTERNATIONAL
(2021)
Article
Biochemistry & Molecular Biology
Debora Singer, Verena Ressel, Matthias B. Stope, Sander Bekeschus
Summary: Under oxidative stress conditions, Hsp27 is highly expressed in prostate cancer cells, playing a crucial role in anti-oxidative effects and blocking apoptosis. The presence of prostate cancer cells leads to ambiguous effects of Hsp27 on myeloid cells, altering their secretion profiles and surface marker profiles, promoting differentiation.
Article
Biotechnology & Applied Microbiology
Yang Liu, Wen Li Zhou
Summary: This study reveals that LINC01315 promotes the growth, metastatic characteristics, and EMT of CRC cells by activating the Wnt/beta-catenin signaling pathway.
Article
Oncology
Xiuting Zhu, Zijin Xiang, Lingxiao Zou, Xueru Chen, Xiangdong Peng, Dabao Xu
Summary: Cervical cancer is a malignant tumor of the female reproductive system. APMAP, a glycosyl type II transmembrane protein, has been found to be highly expressed in cervical cancer tissues and associated with poor prognosis. In vitro experiments demonstrate that APMAP knockdown inhibits the migration ability of cervical cancer cells by activating the Wnt/beta-catenin pathway.
Article
Biochemistry & Molecular Biology
Chaima Cherif, Dang Tan Nguyen, Clement Paris, Thi Khanh Le, Thibaud Sefiane, Nadine Carbuccia, Pascal Finetti, Max Chaffanet, Abdessamad El Kaoutari, Julien Vernerey, Ladan Fazli, Martin Gleave, Mohamed Manai, Philippe Barthelemy, Daniel Birnbaum, Francois Bertucci, David Taieb, Palma Rocchi
Summary: Menin (MEN1) protein is highly regulated by HSP27, overexpressed in high-grade PC and CRPC, and high MEN1 mRNA expression is associated with decreased biochemical relapse-free and overall survival. Silencing Menin helps inhibit CRPC cell proliferation, tumor growth, and restore chemotherapeutic sensitivity.
Article
Environmental Sciences
Qi Qin, Bingwei Yang, Zixuan Liu, Lei Xu, Erqun Song, Yang Song
Summary: The study found that the metabolite PCB29-pQ of polychlorinated biphenyls can induce the metastasis of breast cancer by increasing the expression of cancer stem cell markers and activating the Wnt/beta-catenin pathway, with the overproduction of reactive oxygen species playing a key role in this process.
Article
Biochemistry & Molecular Biology
Xichao Xu, Yi Zhang, Xing Wang, Shun Li, Liling Tang
Summary: In liver cancer, higher liver tissue stiffness enhances malignant cell phenotypes and promotes G1/S transition. NEAT1 is identified as a matrix stiffness-responsive lncRNA regulating proliferation and EMT. The activation of the WNT/beta-catenin pathway by NEAT1 in response to increasing matrix stiffness drives EMT and proliferation in liver cancer cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Minyu Wang, Wanying Huang
Summary: This study found that FOXS1 activates the Hedgehog (Hh) signaling pathway by blocking the ubiquitination of Gli1, thereby promoting the growth and metastasis of prostate cancer cells. High levels of FOXS1 were associated with worse tumor stage and shorter survival in prostate cancer patients.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Oncology
Md Faqrul Hasan, Kavya Ganapathy, Jiao Sun, Ayman Khatib, Thomas Andl, Julia N. Soulakova, Domenico Coppola, Wei Zhang, Ratna Chakrabarti
Summary: The long noncoding RNA PAINT plays a promotive role in prostate cancer progression, with its inhibition reducing cell proliferation and migration while improving drug sensitivity. This study establishes a novel oncogenic function of PAINT in prostate cancer, providing new insights for potential therapeutic strategies.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Engineering, Biomedical
Yani Cui, Mingda Zhao, Yuedi Yang, Ruiling Xu, Lei Tong, Jie Liang, Xingdong Zhang, Yong Sun, Yujiang Fan
Summary: A promising combined chemotherapeutic strategy using a targeted co-delivery nanosystem has been developed to overcome abnormal progression in drug-resistant tumor cells and cancer stem cells. The strategy effectively inhibits the Wnt/β-catenin signaling pathway and EMT process, leading to a reduction in tumor growth and metastasis risk.
ACTA BIOMATERIALIA
(2022)
Article
Oncology
Kazuo Nishimura, Masaki Shiota, Masatoshi Eto, Takefumi Satoh, Angela Stroupe, Caroline Seo, Alyssa Uzumcu, Dianne Athene Ledesma
Summary: This study aimed to understand the perspectives of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) on their quality of life, including unmet needs and what they consider most important in treatment outcomes. A gap analysis was conducted to identify the missing elements from the patient perspective and guide the development of patient-reported outcomes (PROs) for nmCRPC in Japan.
Article
Urology & Nephrology
Takashi Matsumoto, Yoshifumi Hori, Masaki Shiota, Leandro Blas, Motonobu Nakamura, Narihito Seki, Kentaro Kuroiwa, Akira Yokomizo, Futoshi Morokuma, Keijiro Kiyoshima, Masatoshi Eto
Summary: This study evaluated the safety and effectiveness of Ra-223 treatment for bone-metastatic castration-resistant prostate cancer in real-world practice. The study found that the number of treatment cycles, baseline anemia, and bone pain were associated with overall survival.
INTERNATIONAL JOURNAL OF UROLOGY
(2023)
Article
Oncology
Masaki Shiota, Shusuke Akamatsu, Yuya Sekine, Hiroko Kimura, Shintaro Narita, Naohiro Fujimoto, Naoki Terada, Leandro Blas, Tomonori Habuchi, Toshiyuki Kamoto, Yukihide Momozawa, Masatoshi Eto
Summary: This study investigated the prognostic and predictive values of SNPs associated with the prognoses of pharmacotherapy for prostate cancer through their pharmacological mechanisms.
Article
Urology & Nephrology
Ken Lee, Masaki Shiota, Dai Takamatsu, Miho Ushijima, Leandro Blas, Ayami Okabe, Shunichi Kajioka, Shunsuke Goto, Fumio Kinoshita, Takashi Matsumoto, Keisuke Monji, Eiji Kashiwagi, Junichi Inokuchi, Yoshinao Oda, Masatoshi Eto
Summary: This study investigated the impact of extended pelvic lymph node dissection (ePLND) on urinary incontinence (UI) after robot-assisted radical prostatectomy (RARP). The results showed that the urinary continence rate at 1 month postoperatively was lower among patients who underwent ePLND, but there was no significant difference at 3, 6, and 12 months after RARP. Additionally, ePLND and larger prostate volume were associated with an increased UI rate.
INTERNATIONAL JOURNAL OF UROLOGY
(2023)
Article
Pharmacology & Pharmacy
Masaki Shiota, Ryo Inoue, Kojiro Tashiro, Keita Kobayashi, Shizuyo Horiyama, Hiromi Kanji, Masatoshi Eto, Shin Egawa, Jun Haginaka, Hideyasu Matsuyama
Summary: This study aimed to evaluate the efficacy and safety of adding dutasteride, a 5 alpha-reductase inhibitor, to abiraterone for the treatment of castration-resistant prostate cancer. The results showed that the combination therapy achieved a significant reduction in prostate-specific antigen levels without severe adverse events. Genotype analysis revealed that HSD3B1 and SRD5A2 genotypes were associated with drug metabolism and efficacy. These findings provide valuable insights for further investigation and randomized trials.
JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Review
Oncology
Masaki Shiota, Satoshi Endo, Leandro Blas, Naohiro Fujimoto, Masatoshi Eto
Summary: Castration resistance is caused by the abnormal activation of androgen receptor (AR) signaling through intracrine activation of androgen precursors from adrenal glands. To address this, novel AR pathway inhibitors (ARPIs) have been developed to suppress androgen synthesis or AR activation. However, resistance to these ARPIs can occur due to the persistent androgen environment despite intensive AR signaling suppression.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Article
Oncology
Masashi Kaitsumaru, Masaki Shiota, Dai Takamatsu, Leandro Blas, Takashi Matsumoto, Junichi Inokuchi, Yoshinao Oda, Masatoshi Eto
Summary: A 67-year-old man with metastatic prostate cancer showed radiographic progression after 1 year of leuprorelin and enzalutamide treatment. Liver metastasis and elevation of nerve-specific enolase were observed. Biopsy confirmed neuroendocrine carcinoma with BRCA1 mutation detected in the prostate sample. Olaparib treatment achieved significant remission, but was associated with interstitial pneumonia.
INTERNATIONAL CANCER CONFERENCE JOURNAL
(2023)
Article
Oncology
Masaki Shiota, Shuichi Tatarano, Toshiyuki Kamoto, Hideyasu Matsuyama, Hideki Sakai, Tsukasa Igawa, Tomomi Kamba, Naohiro Fujimoto, Yuya Sekine, Hiroko Kimura, Shintaro Narita, Naoki Terada, Yukihide Momozawa, Shusuke Akamatsu, Tomonori Habuchi, Akira Yokomizo, Seiji Naito, Masatoshi Eto
Summary: This study aimed to identify genetic markers that could predict the outcome of androgen-deprivation therapy (ADT) for advanced prostate cancer. Through a genome-wide association study (GWAS), single-nucleotide polymorphisms (SNPs) associated with radiographic progression-free survival (rPFS) and adverse events (AEs) were identified. Validation studies confirmed the association of these SNPs with ADT outcomes, and a genetic prognostic model using these SNPs showed excellent predictive efficacy for progression-free survival and overall survival. The study also revealed SNPs associated with AEs in ADT, such as de novo diabetes mellitus, arthralgia, and de novo dyslipidemia.
ENDOCRINE-RELATED CANCER
(2023)
Article
Urology & Nephrology
Leandro Blas, Masaki Shiota, Shigehiro Tsukahara, Shunsuke Goto, Fumio Kinoshita, Takashi Matsumoto, Keisuke Monji, Eiji Kashiwagi, Junichi Inokuchi, Masatoshi Eto
Summary: This study aimed to compare the detection of clinically significant prostate cancer (csPC) between MRI/ultrasound fusion-targeted prostate biopsy and systematic biopsy (SBx) in biopsy-naive Japanese men. The results showed that MRI/ultrasound fusion-targeted biopsy had better performance in detecting csPC and reduced the detection of non-csPC. However, performing MRI/ultrasound fusion-targeted biopsy alone would miss some csPC, indicating the need for a combination with SBx.
INTERNATIONAL JOURNAL OF UROLOGY
(2023)
Review
Pharmacology & Pharmacy
Masaki Shiota, Miho Ushijima, Shigehiro Tsukahara, Shohei Nagakawa, Leandro Blas, Dai Takamatsu, Satoshi Kobayashi, Takashi Matsumoto, Junichi Inokuchi, Masatoshi Eto
Summary: This study explored the cellular mechanisms involved in steroidogenesis that lead to resistance to the antiandrogen agent darolutamide in prostate cancer. The overexpression of HSD3B1 and its upstream regulator NR5A2 were found in darolutamide-resistant cells, and they were induced by darolutamide treatment and AR knockdown. Inhibiting the NR5A2/HSD3B1 pathway can increase cellular sensitivity to darolutamide, suggesting it as a potential therapeutic strategy to overcome resistance.
DRUG RESISTANCE UPDATES
(2023)
Article
Urology & Nephrology
Masaki Shiota, Naoki Terada, Takahiro Kimura, Hiroshi Kitamura, Toshiyuki Kamoto, Masatoshi Eto, Japanese Urological Oncol Grp JUOG
INTERNATIONAL JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Leandro Blas, Masaki Shiota, Takashi Matsumoto, Yoshifumi Hori, Motonobu Nakamura, Narihito Seki, Kentaro Kuroiwa, Akira Yokomizo, Futoshi Morokuma, Keijiro Kiyoshima, Masatoshi Eto
Summary: This study investigated the effect of bone-modifying agents (BMA) on the occurrence of symptomatic skeletal events (SSE) in patients with bone metastatic castration-resistant prostate cancer (CRPC) treated with Radium-223 (Ra-223). The results showed that BMA use was associated with favorable SSE-free survival.
INTERNATIONAL JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Leandro Blas, Masaki Shiota, Hideaki Miyake, Masayuki Takahashi, Mototsugu Oya, Norihiko Tsuchiya, Naoya Masumori, Hideyasu Matsuyama, Wataru Obara, Nobuo Shinohara, Kiyohide Fujimoto, Masahiro Nozawa, Kojiro Ohba, Chikara Ohyama, Katsuyoshi Hashine, Shusuke Akamatsu, Tomomi Kamba, Koji Mita, Momokazu Gotoh, Shuichi Tatarano, Masato Fujisawa, Yoshihiko Tomita, Shoichiro Mukai, Keiichi Ito, Tokiyoshi Tanegashima, Shoji Tokunaga, Masatoshi Eto, SNiP RCC Investigators
Summary: The study aimed to identify clinical factors associated with tumor response, progression, and survival in nivolumab therapy for advanced clear cell renal cell carcinoma (RCC) in Japanese patients. The results showed that pancreas metastasis, lung metastases, prior cytokine therapy, and serious adverse events were related to objective response. Liver metastases, age >= 75, previous resection of primary sites, and serious adverse events were independent prognostic factors for progression-free survival (PFS). Karnofsky Performance Status < 70, high platelets, previous resection of primary sites, and pathological grade were independent prognostic factors for overall survival (OS). Serious adverse events were associated with objective response, PFS, and OS in patients with prior nephrectomy.
INTERNATIONAL JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Leandro Blas, Masaki Shiota, Shigehiro Tsukahara, Shohei Nagakawa, Takashi Matsumoto, Masatoshi Eto
Summary: This study aimed to compare the adverse event profiles of abiraterone and enzalutamide using a large data set. Adverse event data sets were obtained from the FDA Adverse Event Reporting System database and analyzed using logistic regression. The results showed that abiraterone had a higher incidence of serious adverse events compared to enzalutamide.
Article
Urology & Nephrology
Leandro Blas, Masaki Shiota, Dai Takamatsu, Fumio Kinoshita, Takashi Matsumoto, Ken Lee, Keisuke Monji, Eiji Kashiwagi, Junichi Inokuchi, Masatoshi Eto
Summary: This study analyzed the evolution of BCR-free survival after radical prostatectomy and developed a nomogram incorporating postoperative PSA to predict BCR-free survival.
WORLD JOURNAL OF UROLOGY
(2023)